BioNet, a leading biotech company manufacturing genetically engineered vaccines, and BIA Separations, now part of Sartorius, a leading biochromatography development and manufacturing company, today ...
The clinical potential of mRNA was revealed with COVID-19 vaccines, but that was just the beginning. “Today, this Nobel prize–winning technology is being leveraged for many therapeutic applications, ...
LineaRx will present its Linea™ IVT platform - a combination of an enzymatically produced DNA template (Linea™ DNA IVT template) coupled with a next-generation RNA polymerase (Linea™ RNAP) - as a ...
Imagine you're a scientist, tasked with the challenge of rapidly producing large quantities of high-quality messenger RNA (mRNA) for use in cutting-edge medical treatments. Where do you even start?
The development of nucleic-acid therapeutics, ranging from aptamers and antisense RNA to messenger RNA (mRNA)-based vaccines and gene therapies, is a rapidly evolving industry that has the potential ...
mRNA-based vaccines and gene/cell therapeutics open up new possibilities for medical practitioners in the fight against cancer and infectious or hereditary diseases. However, manufacturing these ...
A platform approach to bioprocessing uses the same set of protocols and systems found during early phase development. Scientists then transfer the protocols, by either scaling-up or scaling-out, ...
Stay ahead in the booming mRNA market, projected to reach $63.28 billion by 2025, with the 3 rd mRNA Process Development & Manufacturing Summit 2025 - Europe’s premier industry-focused forum dedicated ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results